Abstracts tagged "recruitment and rheumatoid arthritis (RA)"

Abstract Number: 2910 • 2019 ACR/ARP Annual Meeting
Improving the Efficiency of Clinical Trial Recruitment Using Electronic Health Record Data, Natural Language Processing, and Machine Learning
Tianrun Cai¹, Fiona Cai ², Kumar Dahal ³, Chuan Hong ⁴ and Katherine Liao ¹, ¹Brigham and Women's Hospital, Boston, ²Stuyvesant High School, New York, ³Brigham and Women's Hospital, Boston, MA, ⁴Harvard Medical School, Boston, MA
Background/Purpose: Efficiently identifying eligible patients is an important component of a successful clinical trial. Billing codes from electronic health record (EHR) data are commonly used…
Abstract Number: 437 • 2017 ACR/ARHP Annual Meeting
Recruitment of RA Trials in the Modern Era: Are United States-Based Trials Still Feasible?
Carla Maldini^1,2, Alfred Mahr³, David T. Felson^4,5 and Michael P. LaValley⁶, ¹Internal Medicine, Hospital Saint-Louis, Paris, France, ²Rheumatology, Hospital Córdoba, Cordoba, Argentina, ³Internal Medicine, University Hospital Saint-Louis, Paris, France, ⁴Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ⁵Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, University of Manchester, Manchester, United Kingdom, ⁶Biostatistics, Boston University School of Public Health, Boston, MA
Background/Purpose: Timely recruitment of patients into interventional trials is necessary for their successful completion. The aim of this study was to evaluate recruitment rates of…
Abstract Number: 1577 • 2012 ACR/ARHP Annual Meeting
Barriers to Recruit Unaffected Family Members of Patients with Rheumatoid Arthritis
Axel Finckh¹, A. Debost-Legrand², Martin Soubrier³, I. von Muehlenen⁴, I. Creveaux², JJ Dubost³, MH Papon², H. Ayadi⁵, P. Migliorini⁶, E. Petit-Teixeira⁷, F. Cornélis² and Eprac⁸, ¹Rheumatology, Geneva University Hospitals, Geneva 14, Switzerland, ²GenHotel-Auvergne, Clermon-Ferrand, France, ³Rheumatology, CHU CLERMONT-FERRAND, Clermont-Ferrand, France, ⁴Rheumatology, Universitäts-Poliklinik, Felix-Platter Spital, Basel, Switzerland, ⁵Sfax university, Sfax, Tunisia, ⁶Pisa university hospital, Pisa, Italy, ⁷GenHotel-Evry-EA3886, Evry, France, ⁸(European pre-RA consortium), Clermont-Ferrand, France
Background/Purpose: Prospective studies are needed to answer key questions on rheumatoid arthritis (RA) screening in at risk populations : (1) How accurately does risk factor…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].